BioMed Research International / 2015 / Article / Tab 1

Research Article

Glycated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1c with Time

Table 1

Baseline characteristics of the study population.

VariablesAll ()

Demographics
 Age (years)61.3 ± 11.6
 Male, (%)204 (71)
 BMI (kg/m2)25.4 ± 3.6
 Waist circumference (cm)88.1 ± 9.0
 Hypertension, (%)195 (57)
 Duration of diabetes (years)1.0 (0–5.0)
Biochemistry profiles
 Creatinine (mg/dL)0.93 ± 0.2
 Estimated GFR (mL/min/1.73 m2)81.5 ± 17.7
 Albumin (g/dL)4.6 ± 0.4
 Total cholesterol (mg/dL)177.2 ± 48.5
 Triglyceride (mg/dL)152.5 ± 110.7
 HDL-cholesterol (mg/dL)47.7 ± 14.3
 LDL-cholesterol (mg/dL)99.7 ± 38.7
Beta-cell function indices at baseline
 Basal glucose (mg/dL)138.0 ± 50.9
 Stimulated glucose (mg/dL)231.8 ± 87.3
 Basal C-peptide (ng/mL)2.35 ± 1.2
 Stimulated C-peptide (ng/mL)6.50 ± 3.3
 ΔC-peptide (ng/ml)4.13 ± 2.6
 PCGR3.24 ± 2.1
 CGI0.08 ± 0.4
Glycemic indices
 GA at baseline (%)19.3 ± 6.6
at baseline (%)7.7 ± 1.6
at baseline (mmol/mol)60.8 ± 16.9
 GA/ ratio at baseline2.47 ± 0.5
 GA at end point (%)16.5 ± 4.9
at end point (%)7.0 ± 1.2
at end point (mmol/mol)53.2 ± 13.1
 GA/ ratio at end point2.33 ± 0.4
 Mean GA (%)16.5 ± 4.0
 Mean (%)7.0 ± 0.9
Medications at baseline
 Insulin, (%)63 (19)
 Metformin, (%)221 (65)
 DPP-IV inhibitor, (%)59 (17)
 Thiazolidinediones, (%)40 (12)
 Sulfonylurea, (%)88 (26)
Medications at 27 months
 Insulin, (%)52 (15)
 Metformin, (%)254 (75)
 DPP-IV inhibitor, (%)98 (29)
 Thiazolidinediones, (%)65 (19)
 Sulfonylurea, (%)99 (29)

Continuous variables were described as mean ± SD or median (quartiles), (%) for categorical variables.
BMI, body mass index; GFR, glomerular filtration rate; GA, glycated albumin; CGI, C-peptide-genic index; PCGR, postprandial C-peptide to glucose ratio.